
Opdivo Approved in Europe for Non-Small Cell Lung Cancer
Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab), in combination with platinum-based chemotherapy as neoadjuvant treatment, …